Pharmathen
Pharmathen S.A., a leading pharmaceutical company headquartered in Greece (GR), has established itself as a key player in the global healthcare industry since its founding in 1975. With a strong presence in Europe, the Middle East, and Africa, Pharmathen focuses on the development, manufacturing, and marketing of innovative generic and specialty pharmaceuticals. The company is renowned for its advanced drug delivery systems and high-quality formulations, which cater to a diverse range of therapeutic areas. Notable achievements include significant investments in research and development, positioning Pharmathen as a trusted partner for both healthcare professionals and patients. With a commitment to excellence and a robust portfolio of products, Pharmathen continues to enhance its market position and contribute to the advancement of global health.
DitchCarbon Score
How does Pharmathen's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharmathen's score of 24 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmathen's reported carbon emissions
In 2023, Pharmathen reported total carbon emissions of approximately 14,911,000 kg CO2e, comprising 9,300,000 kg CO2e from Scope 1 and 5,611,000 kg CO2e from Scope 2. This marks a significant reduction from 2022, where total emissions were about 15,108,000 kg CO2e, with Scope 1 emissions at 13,736,000 kg CO2e and Scope 2 at 8,125,000 kg CO2e. Pharmathen has set ambitious climate commitments, targeting a 45% reduction in greenhouse gas (GHG) emissions by 2030 for both Scope 1 and Scope 2 emissions. This initiative is part of their broader strategy to transition to net-zero emissions by 2050, a pledge formalised in 2023. The company aims to achieve these targets by increasing the share of renewable energy and enhancing energy efficiency across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 13,736,000 | 0,000,000 |
| Scope 2 | 8,125,000 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmathen is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
